Leap Therapeutics Inc . (NASDAQ:LPTX) shares have tumbled to a 52-week low, touching down at $0.8 amidst a challenging market environment. With a market capitalization of just $29.89 million ...

Additional updates on the progression free survival data provide a future catalyst, with LPTX planning to provide updates in 2025. LPTX plans to run a phase 3 study of DKN-01 in colorectal cancer ...

O n Wednesday, H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock rating from Buy to Neutral. The downgrade has intensified ...

Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for ...

Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes Leap Therapeutics' Phase 2 data shows sirexatamab improves ORR in colorectal cancer ...

Short interest in Leap Therapeutics Inc (NASDAQ:LPTX) increased during the last reporting period, rising from 2.46M to 3.21M. This put 9.95% of the company's publicly available shares short.

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...